Oncology · ChemotherapyRegulatory Approvalregulatorymid-term

Alembic's Methotrexate Sodium ANDA220225 Receives AP Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Alembic Pharmaceuticals11 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/4/2026, 6:31:02 PM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of AP status for Alembic's Methotrexate Sodium is significant as it positions Alembic to compete more effectively in the oncology market. Pharma strategy teams should evaluate the potential shifts in market dynamics and pricing strategies that may arise from this approval. Regulatory context from FDA (FDA AP — METHOTREXATE SODIUM (ORIG)) supports the near-term read. Assessment grounded in 27 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market dynamics and pricing strategies for methotrexate products. The strongest clinical anchor is A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Chemotherapy, 8 regulatory and 5 competitive items passed relevance filtering for Alembic Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer. This approval may enhance Alembic's position in the oncology market, particularly in the generic chemotherapy segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — METHOTREXATE SODIUM (ORIG) (FDA). Entity match (methotrexate sodium); Regulatory pathway relevance (nda). While the AP status indicates progress, the final approval and subsequent market entry will be critical in determining compliance and market readiness.

Key Risks

Elevated medium regulatory exposure for Alembic Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Alembic's entry into the market with a generic version of Methotrexate Sodium could lead to price competition, impacting revenue for existing players in the chemotherapy segment.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Lead sponsor: Jazz Pharmaceuticals. Collaborators: Jazz Pharmaceuticals Ireland Limited.
Upside for Alembic Pharmaceuticals may improve if Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval and market entry timeline for Alembic's Methotrexate Sodium.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (SUPPL)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (SUPPL)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (SUPPL)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (SUPPL)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (SUPPL)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Nursing-led Communication Using Mobile Health Information in Breast Cancer Patients Undergoing Concurrent Chemotherapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Alembic Pharmaceuticals
Methotrexate Sodium

Commercial impact

medium

Alembic's entry into the market with a generic version of Methotrexate Sodium could lead to price competition, impacting revenue for existing players in the chemotherapy segment.

Regulatory impact

medium

While the AP status indicates progress, the final approval and subsequent market entry will be critical in determining compliance and market readiness.

What to watch

Monitor for the final approval and market entry timeline for Alembic's Methotrexate Sodium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.